HUM vs UNH: Medicare Momentum Meets Diversified Stability in Managed Care
Key Takeaways
- HUM has shown sharper recent momentum, supported by a strong recovery in its Medicare Advantage Star Ratings, though it carries a higher valuation and greater concentration risk.
- UNH provides broader diversification across insurance and healthcare services, with a steadier multi-quarter earnings recovery and a consistent dividend history.
- Both companies face elevated medical costs, yet each has demonstrated improving medical cost ratios in recent quarters.
- HUM remains closely tied to government-funded Medicare policy, while UNH spans commercial, Medicare, Medicaid, and pharmacy services, which reduces reliance on any single program.
- Recent relative performance has favored HUM, whereas UNH has offered greater stability and trades at a lower valuation multiple.
- For additional context, review HUM Major News and HUM Today's Price Move, along with UNH Major News and UNH Today's Price Move.
- To observe how automated strategies are currently positioned, explore Trending AI Robots.
Why Compare HUM and UNH Now
Humana (HUM) and UnitedHealth Group (UNH) stand out as leading names in U.S. managed care, yet they offer distinct exposures within the sector. HUM focuses primarily on Medicare Advantage for seniors, while UNH combines insurance operations with the diversified Optum platform. This comparison helps investors evaluate concentrated growth potential against broader stability, especially as medical cost trends and regulatory shifts influence performance.
HUM’s Recent Momentum and Key Drivers
HUM derives most revenue from Medicare Advantage plans, complemented by its CenterWell care-delivery segment. A notable regulatory development came with the 2027 Medicare Advantage Star Ratings, where roughly 95% of members are now in plans rated four stars or higher, up from about 20% previously. This improvement has supported a meaningful share-price recovery after a period of pressure. The company has also made progress on margins, with the insurance benefit ratio moving below the 90% target in recent quarters, while CenterWell revenues expanded at a double-digit rate. That said, HUM stays sensitive to Medicare reimbursement policy and medical cost trends, which can add to volatility. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
UNH’s Steady Recovery and Diversified Base
UNH runs the largest U.S. health insurer alongside the Optum platform, which includes care delivery, pharmacy services, and health technology. Under current leadership, management has focused on exiting lower-margin areas to improve profitability. This approach has delivered several consecutive quarters of earnings beats, supported by a better medical care ratio and wider operating margins, with full-year guidance raised multiple times. Diversification helps buffer segment-specific weakness, while a 17-year streak of dividend increases and a forward yield near 2.4% add defensive qualities. Trading has remained measured as investors assess whether margin gains can offset planned enrollment reductions.
Head-to-Head: Concentration Versus Diversification
The main distinction lies in focus versus breadth. HUM essentially represents a leveraged position on Medicare Advantage dynamics, where reimbursement rates, Star Ratings, and senior utilization drive results. This concentration amplifies both the recent rebound and potential downside. UNH, by blending insurance with pharmacy, care delivery, and technology, tends to produce smoother earnings across cycles but caps upside from any one catalyst.
On momentum, HUM has led in recent months due to the Star Ratings repricing. On stability and valuation, UNH holds an edge with a lower forward price-to-earnings multiple and reliable dividend. Growth paths differ as well: HUM emphasizes membership retention and CenterWell expansion, while UNH pursues margin-driven earnings growth alongside deliberate enrollment trimming. Regulatory and medical-cost risks appear more pronounced at HUM, whereas UNH appeals more to income-focused investors.
AI Perspective on the Two Names
From what I see in the data, Tickeron’s AI would likely lean toward UNH for its stronger trend consistency and diversified profile. The pattern of earnings beats, repeated guidance increases, and improving medical cost ratio forms a more durable sequence than a single catalyst-driven move. HUM shows stronger near-term momentum from the Star Ratings improvement, yet its concentrated Medicare exposure and higher valuation introduce greater variability. In probabilistic terms, UNH may suit systematic strategies better, while HUM offers a higher-volatility expression of the sector theme.
Exploring Tickeron AI Trading Bots
In my own research process, I frequently review Tickeron’s Trending AI Robots to understand how automated strategies are currently positioned across the market. The page highlights bots from a large library that best align with prevailing conditions, covering a range of styles, timeframes, and performance metrics. This helps me compare discretionary ideas against data-driven alternatives without committing capital upfront.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
HUM in upward trend: price rose above 50-day moving average on October 02, 2026
HUM moved above its 50-day moving average on October 02, 2026 date and that indicates a change from a downward trend to an upward trend. In 40 of 54 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for HUM just turned positive on October 05, 2026. Looking at past instances where HUM's MACD turned positive, the stock continued to rise in 33 of 49 cases over the following month. The odds of a continued upward trend are 67%.
The 10-day moving average for HUM crossed bullishly above the 50-day moving average on October 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Following a +3.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where HUM advanced for three days, in 218 of 347 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 174 of 239 cases where HUM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
Bearish Trend Analysis
The 10-day RSI Indicator for HUM moved out of overbought territory on October 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 25 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 81%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 64 cases where HUM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 70%.
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HUM as a result. In 46 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 60%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HUM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 66%.
HUM broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 4 (best 1 - 100 worst), indicating outstanding price growth. HUM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.638) is normal, around the industry mean (3.556). P/E Ratio (39.520) is within average values for comparable stocks, (131.597). HUM's Projected Growth (PEG Ratio) (1.304) is slightly higher than the industry average of (0.786). Dividend Yield (0.008) settles around the average of (0.009) among similar stocks. P/S Ratio (0.319) is also within normal values, averaging (0.569).
The Tickeron Profit vs. Risk Rating rating for this company is 92 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HUM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company offers health insurance coverage and related services
Industry ManagedHealthCare
Advertisement